NAFLD is the buildup of excess fat in the liver related to diabetes, obesity, genetics and/or medication. NAFLD affects 30-40% of adults in the US according to the National Institutes of Health and is rapidly becoming the most common liver disease worldwide.
One out of every four people with NALFD have the more progressive form of fatty liver disease called non-alcoholic steatohepatitis (NASH). It is important to know whether or not you have NASH.
NASH is the more severe form of NAFLD in which inflammation and progressive scarring of the liver occur.
In the past, a liver biopsy was necessary to evaluate the level of scar tissue (called “fibrosis”) present in the liver and to distinguish between NAFL and NASH. FibroScan is a simple, noninvasive test, similar to an ultrasound, that measures liver fibrosis and fat content in just a few minutes.
FibroScan is useful for confirming the fatty liver diagnosis and for predicting how much scarring is present in the liver. A biopsy may still be necessary to determine if progression to NASH has occurred.
Call Arizona Liver Health at 480-470-4000 to set up an appointment with one of our experienced providers who can help diagnose your liver condition and put you on a path toward improved outcomes.